KNB.L

Kanabo Group Plc
Kanabo Group PLC - Notice of AGM
31st May 2024, 09:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6544Q
Kanabo Group PLC
31 May 2024
 

31 May 2024

 

Kanabo Group plc

("Kanabo", the "Group" or the "Company")

 

Notice of Annual General Meeting

 

Kanabo Group plc (LSE: KNB)the patient focused healthcare technology and medicinal cannabis company, announces the Notice of Annual General Meeting ("Notice of Meeting") has now been published. The document has been posted to shareholders and is now available to download from the Company's website: https://www.kanabogroup.com/

 

The Company's Annual General Meeting is scheduled to be held on Thursday, 27 June 2024 at 6th Floor, Saddlers House, 44 Gutter Lane, London, EC2V 6BR. The meeting will commence at 11.00 a.m.

 

The voting results of all resolutions put before the 2024 AGM will be announced shortly afterwards.

 

 

Enquiries:

 

Kanabo Group plc

Avihu Tamir, Chief Executive Officer

Assaf Vardimon, Chief Financial Officer

Ian Mattioli,  Non-Executive Chair of the Board

 

 

via Peterhouse Capital

+44 (0)20 7469 0930

Peterhouse Capital Ltd (Financial Adviser and Broker)

Eran Zucker / Lucy Williams / Charles Goodfellow

 

+44 (0)20 7469 0930





 

About Kanabo Group Plc

Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It, an online clinic focused on chronic pain management that provides patients with secondary care.

 

With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider. It offers telehealth consultations, prescriptions and tailor-made treatments.

 

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAEANSFDANLEEA]]>
TwitterFacebookLinkedIn